10:43 AM EDT, 06/04/2024 (MT Newswires) -- Surrozen ( SRZN ) said Tuesday it has initiated the dosing of the first patient in the phase 1b trial for SZN-043 targeting severe alcohol-associated hepatitis.

The open-label, multi-center trial will enroll around 30 patients to assess safety, pharmacokinetics, and efficacy endpoints including model for end-stage liver disease, or MELD, score changes, Lille model score, and overall survival.

Proof-of-concept data is expected by the first half of 2025, the company said.

Shares of the company were down nearly 1% in recent trading.

Price: 11.30, Change: -0.11, Percent Change: -0.96